Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 56.9%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 117,700 shares, an increase of 56.9% from the June 15th total of 75,000 shares. Based on an average daily trading volume, of 339,400 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.6% of the shares of the company are short sold.

Institutional Trading of Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC purchased a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned 0.09% of Xilio Therapeutics as of its most recent SEC filing. 54.29% of the stock is owned by hedge funds and other institutional investors.

Xilio Therapeutics Stock Up 2.0 %

XLO opened at $1.02 on Friday. The stock has a market capitalization of $37.65 million, a price-to-earnings ratio of -0.40 and a beta of -0.09. The firm has a 50 day moving average price of $1.03 and a 200-day moving average price of $0.90. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.94.

Xilio Therapeutics (NASDAQ:XLO) last announced its earnings results on Tuesday, May 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.29). As a group, analysts expect that Xilio Therapeutics will post -1.48 earnings per share for the current year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.